MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Country |
 USA |
IPO year |
2017 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
164 M |
Market Cap[1] |
$ 3.32 B |
EBITDA (LTM) |
$ -471 M |
P/E (LTM) |
-7.28 |
P/S (LTM) |
10.28 |
EPS (LTM) |
-2.87 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Akebia Therapeutics
AKBA
|
$ 1.48 | -1.67 % | $ 277 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.7 | -0.34 % | $ 5.99 B | Nasdaq Global Market |  Irlanda |
 |
ANI Pharmaceuticals
ANIP
|
$ 79.9 | -0.55 % | $ 1.54 B | Nasdaq Global Market,SPB | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market |  Canada |
 |
Aptorum Group Limited
APM
|
$ 0.88 | 5.24 % | $ 4.8 M | Nasdaq Global Select Market |  China |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Adagene
ADAG
|
$ 2.66 | -0.37 % | $ 150 M | Nasdaq Global Market | China |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.5 | -2.1 % | $ 8.42 B | Nasdaq Capital Market |  Australia |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 110.96 | 0.56 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Cabaletta Bio
CABA
|
$ 2.48 | 1.64 % | $ 2.9 M | Nasdaq Global Select Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Compugen Ltd.
CGEN
|
$ 1.75 | 2.05 % | $ 157 M | Nasdaq Global Market,SPB |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Ascendis Pharma A/S
ASND
|
$ 220.07 | -0.88 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 41.12 | -0.46 % | $ 4.24 B | Nasdaq Capital Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 9.23 | 2.9 % | $ 1.44 B | NYSE | Britain |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 24.29 | -0.67 % | $ 2.88 B | Nasdaq Capital Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 49.94 | 0.48 % | $ 4.21 B | Nasdaq Global Market,SPB |  Schweiz |
|
Champions Oncology
CSBR
|
$ 6.54 | -0.15 % | $ 89.3 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 4.45 | 5.33 % | $ 9.68 B | NYSE American | Israel |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.46 | - | $ 373 M | Nasdaq Global Select Market | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
$ 14.48 | -0.28 % | $ 4.47 B | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.